This therapeutic strategy targets pericyte survival and function through PDGFR-β signaling agonism to restore blood-brain barrier integrity in early neurodegeneration. Pericyte loss is among the earliest detectable pathologies in Alzheimer's disease — preceding amyloid deposition, tau pathology, and neuronal loss — yet no clinical program targets pericyte preservation. PDGF-BB/PDGFR-β signaling is the master regulator of pericyte recruitment, survival, and contractile function. A pericyte-protective strategy could prevent BBB breakdown, reduce neuroinflammation by blocking peripheral immune infiltration, and paradoxically improve drug delivery by maintaining organized transcytosis pathways.[1][2]
The neurovascular unit depends critically on pericytes for BBB integrity, cerebral blood flow regulation, and neurovascular coupling. Pericyte dysfunction and pericyte loss drive a vicious cycle in neurodegeneration:[1:1]
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 9/10 | No clinical programs target pericyte preservation; PDGFR-β agonism for neuroprotection is entirely unexplored |
| Mechanistic Rationale | 8/10 | Pericyte loss clearly precedes and accelerates AD pathology; PDGFR-β is the canonical survival pathway |
| Addresses Root Cause | 7/10 | Addresses BBB breakdown (an upstream initiating event) but not protein aggregation directly |
| Delivery Feasibility | 6/10 | Paradox: the target is the BBB itself, so circulating biologics have access; but peptides need stabilization for CNS effects |
| Safety Plausibility | 6/10 | PDGFR-β stimulation risks fibrosis and smooth muscle proliferation; pericyte-targeted delivery needed for safety |
| Combinability | 8/10 | Orthogonal to anti-amyloid, anti-tau, and anti-inflammatory therapies; BBB restoration could improve delivery of all CNS drugs |
| Biomarker Availability | 7/10 | CSF sPDGFRβ (soluble receptor shed during pericyte damage) is a validated biomarker of pericyte injury; DCE-MRI measures BBB permeability |
| De-risking Path | 7/10 | Pdgfrb-CreERT2 pericyte ablation mice available; PDGFR-β signaling well-characterized; ApoE4 knock-in mice show pericyte loss |
| Multi-disease Potential | 8/10 | BBB breakdown documented in AD, PD, ALS, vascular dementia, TBI, MS — pericyte protection relevant across neurology |
| Patient Impact | 7/10 | BBB preservation could slow disease progression and improve efficacy of co-administered drugs |
| Total | 73/100 |
| Disease | Relevance | Rationale |
|---|---|---|
| Alzheimer's Disease | High | Pericyte loss is one of the earliest detectable changes; BBB breakdown accelerates Aβ accumulation[1:2] |
| Vascular Dementia | High | Small vessel disease and BBB breakdown are the primary pathologies |
| Cerebral Small Vessel Disease | High | Pericyte dysfunction drives white matter lesions and lacunar infarcts |
| Parkinson's Disease | Medium | BBB disruption in substantia nigra documented; contributes to neuroinflammation |
| ALS | Medium | Blood-spinal cord barrier breakdown documented in ALS patients and SOD1 mice[6] |
| Traumatic Brain Injury | Medium | Acute pericyte loss contributes to secondary injury |
| Phase | Duration | Key Milestones |
|---|---|---|
| Lead Optimization | 6-12 months | Screen brain-penetrant candidates, optimize PK/PD |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in patients |
| Risk | Likelihood | Impact | Mitigation |
|---|---|---|---|
| Brain penetration failure | Medium | High | Early PK/PD screening |
| Off-target effects | Low | Medium | Selectivity profiling |
| Clinical trial recruitment | Low | Medium | Multi-center design |
Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018. ↩︎ ↩︎ ↩︎
Bell RD, Winkler EA, Sagare AP, et al. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010. ↩︎ ↩︎
Ryu JK, Petersen MA, Murray SG, et al. Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nature Communications. 2015. ↩︎
Sagare AP, Bell RD, Zhao Z, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nature Communications. 2013. ↩︎
Hall CN, Reynell C, Gesslein B, et al. Capillary pericytes regulate cerebral blood flow in health and disease. Nature. 2014. ↩︎
Winkler EA, Sengillo JD, Sullivan JS, Henkel JS, Bhatt P, Bhatt I, Zlokovic BV. Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathologica. 2013. ↩︎